Dr.Shravan Masurkar, M16534, Dr. Shrinivas M Joshi, Dr. Sameera. V. V, Dr. Apoorva A G, Dr. Guruprasad Ayachit
METHODS:A prospective analysis was performed in patients with neovascular AMD (Group 1),macular oedema secondary to RVO (Group2) and DME (Group3) who received intravitreal Razumab at baseline.Snellen visual acuity,anterior and posterior segment evaluation including fundus photo and optical coherence tomography imaging was done at Day 0,1,7 and 30.
RESULTS:119 eyes of 95 patients received Razumab injection between November 2015 and April 2016. No serious drug-related ocular adverse events were identified.Mean pre-treatment best corrected visual acuity (BCVA) was 0.59 ± 0.43 logMAR with CMT 345.90 ± 128.84 μm and post injection BCVA at day 30 was 0.50 ± 0.37 logMAR with CMT reducing to 287.65 ± 90.29 μm indicating statistical significance (p=0.0467) and (p<0.0001) respectively for all groups.
CONCLUSION:Off-label new biosimilar Razumab therapy was well tolerated over a month with improvements in BCVA and CMT in all groups and can be considered to be most cost effective down the line.